NewsRoom Articles

ThursdayMay 19, 2022 9:45 am

Flora Growth Corp. (NASDAQ: FLGC), A Company Revolutionizing the Plant-Based Wellness and Lifestyle Industry

Flora Growth has been building a design-led collective of plant-based wellness and lifestyle brands Through the work done by its pharma division, the company earned over $31.5 million in gross proceeds in the year ended November 2021 The company still maintains its revenue guidance projection of $35-45 million for 2022, attributed mainly to product diversification initiatives, strengthening its supply chain, and adoption of cost-effective cultivation practices Since its inception, Flora Growth (NASDAQ: FLGC) has remained committed to building a design-led collective of plant-based wellness and lifestyle brands. This objective has defined Flora Growth’s three central pillars- wholesale cannabis, pharmaceutical cannabis,…

TuesdayMay 17, 2022 10:30 am

Flora Growth Corp. (NASDAQ: FLGC) Bolsters its Board of Directors following Tim Leslie’s Addition and Luis Merchan’s Appointment as Chairman

Luis Merchan, Flora Growth’s CEO, will serve as the new Chairman of the Board Tim Leslie, the Chairman of the company’s Advisory Board, will serve on its Board and audit committee Flora Growth’s management is confident that these changes will position it as a U.S-based issuer while increasing its access to U.S-based investment Since the beginning of 2022, Flora Growth (NASDAQ: FLGC) has been making strategic moves that strengthen its human resources and reinforce its executive team. The company kicked off the year with the appointment of Tim Leslie as the Chairman of its newly formed Advisory Board (https://cnw.fm/suiqd). Later,…

WednesdayMay 11, 2022 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry

Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment Lexaria has also made some significant progress in the use of its technology for the enhanced delivery of antiviral drugs It hopes that before the end of 2022, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation Lexaria Bioscience (NASDAQ: LEXX), since its inception, has been pushing the boundaries of…

MondayMay 09, 2022 9:45 am

Advanced Container Technologies Inc. (ACTX) Offers New Tech with GrowPod Automated, Indoor Micro-Farms

Innovators in food supply field have been developing new technologies such as indoor farms These game-changing micro-farms can be built anywhere ACTX is the exclusive distributor of GrowPods in the United States With global supply chain issues grabbing headlines and impacting almost every industry, potential solutions in any sector are certain to capture attention. Hence Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of GrowPods, is definitely seeing interest in the environmentally controlled micro-farms that allow cultivation of ultraclean crops year-round. “Land preservation and regenerative organic agriculture practices are critical to solving food insecurity and combating climate change,” reported…

ThursdayMay 05, 2022 12:25 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands

In its most recent oral nicotine study, Lexaria established that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls Lexaria hopes to evidence in its upcoming human oral nicotine study NIC-H22-1, that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to currently sold brands Lexaria’s DehydraTECH technology works with new and existing drugs, processing them into a final form that increases bioavailability, speeds up onset and improves effectiveness that can allow for smaller doses The company also recently announced…

ThursdayMay 05, 2022 11:29 am

Advanced Container Technologies Inc. (ACTX) GrowPods ‘Ideally Suited’ for New USDA Food System Initiative

Up to $400 million has been made available to support food purchases with emphasis on purchasing from underserved farmers, ranchers Agency strengthens efforts to provide emergency food assistance, expand economic opportunity ACTX GrowPods could be valuable tool in effort to build resilient local, regional food-production capabilities In an effort to provide transform the food system and build a better food system after the global pandemic exposed weaknesses in the system, the U.S. Department of Agriculture (“USDA”) established a Local Food Purchase Assistance Cooperative Agreement Program (“LFPA”) last year (https://cnw.fm/omE5D). Advanced Container Technologies (OTC: ACTX), a company focused on the business…

TuesdayMay 03, 2022 9:30 am

Prime Harvest Inc. Is ‘One to Watch’

Prime Harvest is leveraging a long-term strategy of investing in the growth and scale of licensed assets in California, anchored by the power of data-driven technology Its flagship brand, Jaxx Cannabis, aims to use technology to facilitate a true customer-centric culture while enhancing the overall craft cannabis experience The company is committed to the goal of creating a more sustainable environment, now and in the future Prime Harvest is a proud member of the Community Alliance Program, a foundation that seeks to make a difference in local communities The company’s leadership team boasts over 100 years of combined hands-on experience…

TuesdayMay 03, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Update on its Patented DehydraTECH(TM) Technology, Including the Approval of New Patent

Lexaria received its 25th patent – and the first patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs The company is seeking IND approval from the FDA and has commenced its human HYPER-H21-4 study for hypertension with DehydraTECH-CBD, with results expected in Q3 2022 Lexaria is also commencing its human oral nicotine study, NIC-H22-1 to compare Lexaria's DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the US such as ON! and Zyn Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced some positive news that further promotes…

MondayMay 02, 2022 9:30 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Strengthens Financial Profile with Debt Reduction, Adjustments to Revenue Strategy

Red White & Bloom Brands is a multi-state cannabis operator based in Canada and focused on developing revenue opportunities in strong U.S. cannabis markets such as Michigan, Florida and California The company recently announced it has eliminated $115 million in debt liabilities as part of its efforts to streamline its financial operations during a period when many companies are struggling with the effects of the COVID pandemic Red White & Bloom’s debt reduction includes cutting over $22 million in annual expenses The company has solidified its foothold in Michigan with acquisitions that have allowed it to become vertically integrated and…

FridayApr 29, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH

Lexaria just received another patent for DehydraTECH(TM): this time for the enhanced delivery of antiviral drugs This becomes the company’s 25th patent granted worldwide and the 10th granted in the U.S. It adds to the company’s growing patent portfolio, which also consists of ~50 pending patents worldwide Over the 2022 calendar year, the company seeks to also pursue regulatory and commercial advancement In 2016, Lexaria Bioscience (NASDAQ: LEXX) received its first United States patent grant and over the years, the company has been aggressive at broadening its patent suite, a move which it has attributed to refining the patent claims…

News and publishing service for CBD related companies

Contact us: 303.498.7722